Background
Helicobacter pylori(H.pylori) is a gram-negative bacilli, which colonizes the stomach and causes 50% infection of the population worldwide. Chronic infection with H.pylori is the main cause of various gastroduodenal diseases such as gastritis, peptic ulcer and is also a risk factor for gastric adenocarcinoma and lymphoma. In general, the host elicits robust immune response to H.pylori infection. However, the infection is often persistent and lasts for very long time, suggesting that H.pylori may evade both innate and adaptive immune responses.
The mechanism of protection against
H.pylori infection remains largely unknown, but there are growing evidences to support a pivotal role of CD4
+ T helper cells (Th cells) in the immune response against
H.pyori infection[
1]. Th cells are activated when the peptide antigens are presented by MHC II molecules, which are expressed on the surface of antigen presenting cells (APCs). Once activated, Th cells are divided rapidly and secrete cytokines to regulate the active immune response. When MHC II mutant mice are challenged by
H.pylori, greater colonization of
H.pylori in mutant mice are formed than in WT mice, suggesting that the mutation in MHC II on APC cells fails on the presentation of epitopes peptides. The level of anti
H.pylori antibody in challenged wild-type mice is high but not detectable in mutant mice. Moreover, oral immunization with
H.pylori whole-cell lysates reduced infection in wild-type and MHC I
-/- mice but not in MHC II
-/- mice[
1]. All these observations suggest that Th cells may play an important role in protection of
H.pylori infection.
Antibiotic treatment is the most effective therapy for
H.pylori infection. Unfortunately, this strategy often results in many side-effects, such as poor patient compliance, production of antibiotic resistant strain and re-infection. Recently, developing effective vaccines against
H.pylori has attracted much attention. Epitope-based vaccine design (EBVD) represents an alternative way to improve native antigen which can not evoke optimal immune response to pathogen[
2]. The conserved epitopes identified by EBVD have been shown to not only elicit specific immune response but also increase potency and breadth of immune response. One of the key steps in EBVD approach is the identification of appropriate epitopes to obtain effective response.
Lpp20 is an outer membrane lipoprotein of
H.pylori and also sheds from surface to medium[
3,
4]. Lpp20 is one of major antigens recognized by rabbit antiserum against
H.pylori[
5]. Passive anti-Lpp20 antibody transfusion decreases
H.pylori infection in
H. pylori infected mice[
3]. Therefore, Lpp20 is an excellent vaccine candidate antigen for
H.pylori infection.
In this study, we hypothesized that modified candidate antigens of Lpp20 may trigger more effective immune response induced by H.pylori infection. Two identified peptides on Lpp20 were able to stimulate CD4+ T cell proliferation and additive secretion of IFN-γ. These results provide us better understanding of cellular immunity against H.pylori infection and insights into the design of H.pylori vaccines.
Methods
Prediction and synthesis of Lpp20 Th cell epitopes
Amino acid sequence of Lpp20 for
H.pylori strain NCTC11639 was acquired from NCBI protein database (No. AAZ13599 submitted by us[
6]). For BALB/c mice, MHC II molecule includes I-A
d and I-E
d types. Potential I-A
d and I-E
d restricted Th cell epitopes of Lpp20 were predicted by SYFPEITHI system[
7]. Five highest-scored I-A
d restricted and five highest-scored I-E
d restricted putative epitopes were selected. After further analysis, eight epitopes were synthesized by Chinese peptide Ltd.Co. (Hangzhou, China). The peptides were supplied as lysophilized powder and dissolved in dimethyl sulfoxide (DMSO) at a concentration of 4 mg/ml, sterilized with filter and stored in aliquots at −20°C. Peptides were diluted with RMPI 1640 incomplete culture medium (Gibco) before experiments. Recombinant Lpp20 (rLpp20) was expressed in Escherichia coli previously[
6].
Mice and immunization
Female BALB/c mice aged 6 ~ 8 weeks were purchased from Experimental Animal Center of Southern Medical University and approval to conduct this study was granted by the Ethics Committee of Southern Medical University. For rLpp20 immunization, mice were administered with 100 ug of rLpp20 emulsified in Complete Freund’s adjuvant (CFA; Sigma) by subcutaneous route in the four limbs and boosted 2 weeks later with the same protein in incomplete Freund’s adjuvant (IFA; Sigma). For peptides immunization, mice were administered with 100ug of peptide in IFA using the same procedure. Mice were used for experiments at 7–10 days after immunization. Mice immunized with PBS were used as control. Five mice were included in each group.
Preparation of antigen presenting cell (APC)
Mice were sacrificed and spleens were harvested. After treatment with erythrocyte lysing buffer (0.83% NH4Cl2), splenocytes were resuspended to 5 × 107 cells /ml in PBS with the addition of 100 μl mitomycin-C (Sigma; 500 μg/ml in PBS). Then these cells were incubated for 20 min at 37°C followed by three washes with RPMI 1640. The supernatant was discarded and the pelleted cells were resuspended in RPMI 1640 as APCs.
CD4+ T cells proliferation assay
Mice were euthanized and spleens were harvested after the last immunization. Single-cell suspensions were obtained by homogenizing spleens and passing cells through a 70 mm cell strainer. The erythrocytes were removed by Ammonium Chloride Lysing Reagent (BD Biosciences, PharMingen). CD4
+T cells were negatively sorted using mouse CD4 negative isolation kit (Dynal). Routinely, the resultant cells were >95% CD4
+ T cell as determined by flow cytometry. To stimulate CD4
+ T cells, peptides or rLpp20 were added into the mixture of APCs (4 × 10
5) and CD4
+ T cells (2 × 10
5) which were resuspended in 200 μl RPMI-1640 complete cultured (RPMI-1640, 10% fetal bovine serum, 2 mM glutamine, 100 U of penicillin/ml, 100 U of streptomycin/ml, 50 mM 2-mercaptoethanol, and 25 mM HEPES). Culture without any antigen was served as negative control. Other controls were APCs without CD4
+ T cells in the presence of ConA and CD4
+ T cells without APC in the presence of peptides. Culture was set up in triplicate and incubated at 37°C, 5% CO
2 for 5 days. During the final 16–18 h, each well was pulsed with 1 μCi of
3H] thymidine (Amersham Biosciences, Piscataway, NJ).
3H] thymidine incorporation was measured in a liquid scintillation counter after collecting cells onto glass fiber filters. The stimulation index (SI) was determined by comparing
3H] thymidine incorporation in the peptide-stimulated wells with unstimulated wells using the following equation: SI = mean cpm of peptide wells/mean cpm of no peptide wells. Experiments were independently repeated three times. Proliferative response was considered positive when SI was ≥2 at the 95% confidence level[
8,
9]. To investigate if there was any additive or subtractive interaction among the identified epitopes, the peptides were pooled to stimulate CD4
+ T cells from mice immunized with rLpp20.
MHC restriction studies
To detect MHC restriction for presentation, mAbs (eBiosciensce) against the murine I-Ad (clone 39-10-8), I-Ed (clone14-4-4S), and MHC class I (H-2d) (clone 34-1-2S) molecules were added to cultures and their capacity to inhibit peptide-specific proliferation were measured. Briefly, purified CD4+ T cells from mice primed with rLpp20 were preincubated with mAbs for 2 h at 37°C and then peptides(1.25 μg/ml) were added and incubated at 37°C, 5% CO2 for 5 days. The proliferation induced by peptides was tested as described above. Culture incubated with peptides without mAb served as negative control.
Cytokine profile analysis by ELISA and real-time PCR
To detect the subset of CD4+ T cells, cytokine profile in response to peptide L1 and L2 was analyzed. CD4+ T cell culture supernatant (100 μl each) was collected after 72 h and cytokines were quantified by IFN-γ and IL-4 ELISA kits (eBioscience, San Diego, CA, USA). Cytokine production was calculated from the titration of supplied calibrated cytokines standards. Results were corrected for dilution of the sample to yield concentration in pg/ml. Meanwhile, mRNA expression level of IFN-γ and IL-4 were quantified. Total RNA from splenic lymphocytes was isolated using Trizol RNA isolation kit (Roche). Real time PCR was performed for IFN-γ, IL-4 and β-actin (as internal control) using SYBR Green Supermix in a 96-well plate of the ABI Prism 7500 Fast Sequence Detector (Applied Biosystems). 25 μl reaction mixtures contained 1 μl 100 X diluted cDNA, 12.5 μl 2X Power SYBR Master Mix (Applied Biosystems) and 150 nM of each primer. The primer sequences were listed as below:
IFN-γ: 5′-TGTCATCCTGCTCTTCTTTCTC-3′
5′-GACCTCAAACTTGGCAATACTC-3′
IL-4: 5′-AACTCAAGTGGCATAGATGTGG-3′
5′-GACCTCAAACTTGGCAATACTC-3′
β-actin: 5′-ATCCGTAAAGACCTCTATGCCAACA-3′
5′-GTCGCCTTCACCGTTCCAGTTT-3′
The relative fold change of mRNA level of IFN-γ and IL-4 was calculated using the delta delta Ct (threshold cycle) method[
7]. The averages and standard deviations were determined from triplicate datasets. ΔCt is the difference between Ct of target mRNA and Ct of β-actin for each group.
Flow cytometry analysis
Splenic lymphocytes stimulated with L1 and L2 respectively were phenotyped by double staining with anti-CD4 and CD3 mAbs (eBiosciensce) and fluorescence activated cell sorter. One million cells were collected and preincubated with rat IgG2b anti-mouse CD16/CD32 (clone 93, eBiosciensce) for 10 min to exclude unspecific Fc-receptor-mediated binding. After washing in cold PBS (2% bovine serum albumin), the cells were stained with PE-labeled anti-CD4 (clone RM4-5) and FITC-labeled anti-CD3 (clone 145-2C11) mAbs for 30 min on ice. Unspecific staining was controlled with appropriate FITC and PE labeled isotype controls respectively. The samples were analyzed with FACS Calibur flow cytometer and the data were analyzed by CELLQuest software (BD Biosciences).
Statistical analysis
Data were representative of three independent experiments and expressed as mean ± standard deviation (SD). The results were processed using Student’s t-test with SPSS13.0 program. Significance was defined by a value of P < 0.05.
Discussion
CD4
+ T cells recognize antigenic epitopes in the context of MHC II molecules on APCs. Many investigations of
H.pylori infection have demonstrated that the protective immune response is mediated by CD4
+ T cells but not by CD8
+ T cells. Therapeutic immunization reduced
H.pylori colonization in stomach in mice lacking B cells, suggesting that T cell is protective[
10]. Oral immunization with
H. pylori whole-cell lysates reduced infection in wild-type and MHC I
-/- mice, but it had no effect on MHC II
-/- mice. Anti-
H.pylori antibody levels in serum showed a dominant IgG in immunized wild-type and MHC I
-/- mice but no detectable IgG in MHCII
-/- mice[
1]. CD4
+T cells from
H.pylori antigen immunized mice were sufficient to transfer protective immunity to the immunodeficient recipients[
11]. Taken together, identification and characterization of the Th cell eptioptes of Lpp20 would contribute to a better understanding of protective immunity to
H.pylori and facilitate the development of effective immunotherapeutic and immunoprophylactic strategies.
The identification of CD4
+ T epitiopes has traditionally been done either by sequencing of eluted peptides bound to specific MHC II molecules from APCs or by screening panels of overlapping peptides. These two methods were successfully performed to identify many T epitopes; however, the method of sequencing eluted peptide is potentially cumbersome to identify epitopes from multiple processed antigens but not specifically a single antigen. The overlapping peptide method needs synthesis of a series of overlapping peptides, thus making it an expensive, laborious and time-consuming process. In addition, this method possibly misses junctional epitopes that might be present in the overlapping regions, though spanning the entire length of the antigens[
12]. These considerations lead us to use the combination of prediction and experiments to identify Th cell epitopes. Although it is possible to miss potential epitopes, this method represents a quick and effective approach to identify epitopes. Here we used algorithm program with T cell biological analysis to identify Th cell epitopes on Lpp20. Eight epitopes were selected to be synthesized and measured, of which two (L1 and L2) were identified to be Th cell epitopes, which were located at residues 83-97aa (L1) and 58-72aa (L2). Interestingly, L2, which was predicted to be both restricted by I-A
d and I-E
d, effectively stimulated more proliferation of splenic CD4
+ T cells than L1, which was predicted to be I-A
d restriction. Our results indicate that the combination of prediction and experiments is an easy and effective way to identify Th cell epitopes. The present findings may be valuable for the development of epitope-based vaccines against
H.pylori.
CD4
+ T cells can polarize to Th1 or Th2 cells based on their profile of cytokine. Th1 cells produce IFN-γ, IL-2 and TNF-β that mediate cellular immunity. In contrast, Th2 cells produce IL-4, IL-5, IL-10 and IL-13, which are responsible for humoral immunity[
13]. It is generally believed that polarized Th1-type response is involved in the pathogenesis of
H.pylori infection[
14‐
17]. But Whether Th1 or Th2 type immune response is responsible for protective immunity is still unclear. Some studies support that Th2 response characterized by IL-4 secretion is important to clear
H.pylori[
18‐
21]. On the contrary, some studies reveal that protection against
H.pylori is mediated by predominantly Th1-type immune responses independent of IL-4[
22,
23]. Moreover, some researchers demonstrate that a mixed Th1-Th2 phenotype is correlated with the protective immunity against
H.pylori infection[
24]. Therefore, identification of Th1 and Th2 type epitopes may help us investigate the role of Th1 or Th2 type responses on pathogenesis and immunity of
H.pylori infection. Meanwhile, it is also a pivotal step for a rational modulation of immune response by developing effective multiple Th1 or/and Th2 epitope vaccine. In this study, we found that L1 and L2 were both Th1-type epitopes and induced CD4
+ T cell to mainly secrete IFN-γ.
In conclusion, we have identified two Th1 cell epitopes on Lpp20. Peptide L1 is I-A
d restricted epitope and peptide L2 is both I-A
d and I-E
d restricted epitopes. These two peptides both evoked Th1-type response. In addition, the two pooled peptides stimulated significantly more elevated T cell responses, showing an additive effect. We have identified one B cell epitope of Lpp20 using phage displayed library previously[
6]. Next, we will combine these two Th epitopes and one B cell epitope to evaluate whether the combined epitopes can induce protective response and prevent
H.pylori infection better than the whole Lpp20 protein in BALB/c mice. The data from our mouse model will provide significant information for further study of epitope-based vaccine.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
YL designed and contributed the majority of the bench work. YJ, YX and SZ expressed the recombinant Lpp20 and participated in real-time PCR and ELISA. LZ and SZ analyzed the statistical data for the experiments. JL immunized the animals. DH isolated and culture CD4+ T cell. YN designed the experiments. YL wrote the manuscript and all authors have read and approved the final manuscript.